MiCardia Corporation Receives Notification of a New German Reimbursement Code for the Adjustment of Its enCorSQ Mitral Valve Repair System
Published: Jan 23, 2013
IRVINE, Calif.--(BUSINESS WIRE)--MiCardia Corporation announced today it has received notification that a new German reimbursement code has been approved for the adjustment of the Company’s enCorSQ Mitral Valve Repair SystemTM. This new code will provide additional reimbursement for the enCorSQ, a breakthrough approach to the long-term treatment of mitral valve disease. In particular, this new code will reimburse the follow-up treatment of recurrent mitral regurgitation which statistically occurs in 15-30% of all patients with surgically repaired mitral valves. The Company believes that the enCorSQ System is the only available technology that provides such follow-up therapy for the heart’s mitral valve.